Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Trial Profile

An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 13 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top